CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing an oral vaccine to prevent Helicobacter pylori infections, which can lead to serious gastrointestinal diseases. It combines advanced antigens, adjuvants, and a flexible delivery system to enhance safety and effectiveness, aiming for a product that can enter human clinical trials.
Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer.
Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness.
However, with much greater knowledge of the molecular basis of infection an…
SUBLIMITY THERAPEUTICS LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, VASTRA FROLUNDA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Switzerland, Bioggio
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Ireland, DUBLIN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Ireland, DUBLIN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
